Aims and Scope
Clinical Lung Cancer is a peer-reviewed medical journal that has been published by Elsevier since 2011. It was established by the CIG Media Group in 1999.
Key Metrics
7.5
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.005 - 0.01
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.84
5-Year SI
5-year SI
- N/A 2-year SI
- 0.84 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q2
Oncology
SJR
- Q1 Oncology
- Q2 Cancer Research
- Q1 Pulmonary and Respiratory Medicine
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.18
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
3 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
38%
4 to 6 months
49%
7 to 9 months
10%
Above 9 months
3%
Did you find this useful?
Thank you for your feedback.
Indexed in the following public directories
-
Web of Science -
Scopus -
SJR
Topics Covered
- Cancer
- Lung cancer
- Anaplastic lymphoma kinase
- Progression-free survival
- Immunotherapy
- Epidermal growth factor receptor
- Overall survival
- Chemoradiotherapy
- Lung
- Receptor tyrosine kinase
- Exon
- Multivariate analysis
- Squamous cell lung cancer
- Quality of life
- Objective response
- Concurrent chemoradiotherapy
- Computed tomography
- Positron emission tomography
- Lymph node
- Radiation Pneumonitis
Journal Specifications
| Overview | |
| Publisher | CIG MEDIA GROUP, LP |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1999 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Clinical Lung Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report
- 1 Dec 24
- Clinical Lung Cancer
-
Full paper
A phase II, open label, single-arm study on the efficacy of cabozantinib in patients with advanced/metastatic nonsmall cell lung cancer harboring MET exon 14 alterations who developed acquired resistance to tepotinib or capmatinib (CAPTURE trial)
- 1 Dec 24
- Clinical Lung Cancer
-
Full paper
Neratinib Efficacy in Patients with Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings from the SUMMIT Basket Trial
- 1 Dec 24
- Clinical Lung Cancer
-
Full paper
PEARL: A multicenter phase 2 study of lorlatinib in patients with ALK-rearranged NSCLC and central nervous system disease
- 1 Dec 24
- Clinical Lung Cancer
-
Full paper
Editorial Board
- 1 Dec 24
- Clinical Lung Cancer
-
Full paper
Brief Report: Osimertinib Plus Capmatinib for Patients with MET-Altered EGFR-Mutant NSCLC following progression on front line therapy
- 1 Dec 24
- Clinical Lung Cancer
Scite analysis
Powered by scite_
2.8k articles received 37.4k citations see all
- 1,664 Supporting
- 34,882 Mentioning
- 314 Contrasting
Editorial notices
- 1 Retractions
- 3 Withdrawals
- 0 Corrections
- 8 Errata
- 0 Expression of Concern
FAQs
How long has Clinical Lung Cancer been actively publishing?
Clinical Lung Cancer has been in operation since 1999 till date.
What is the publishing frequency of Clinical Lung Cancer ?
Clinical Lung Cancer published with a Bi-monthly frequency.
How many articles did Clinical Lung Cancer publish last years ?
In 2024, Clinical Lung Cancer published 160 articles.
What is the eISSN & pISSN for Clinical Lung Cancer ?
For Clinical Lung Cancer,eISSN is 1938-0690 and pISSN is1525-7304.
What is Citescore for Clinical Lung Cancer ?
Citescore for Clinical Lung Cancer is 7.5.
What is SNIP score for Clinical Lung Cancer ?
SNIP score for Clinical Lung Cancer is 1.18.
What is the SJR for Clinical Lung Cancer ?
SJR for Clinical Lung Cancer is Q2.
Who is the publisher of Clinical Lung Cancer ?
CIG MEDIA GROUP, LP is the publisher of Clinical Lung Cancer.